Novo Nordisk and AWS accelerate drug discovery with AI
Jakarta (ANTARA) - Novo Nordisk and Amazon Web Services (AWS) have entered a strategic partnership to accelerate drug discovery and modernise operations through the use of artificial intelligence (AI) and cloud computing technology.
Novo Nordisk President and CEO Mike Doustdar said in an official statement in Jakarta on Thursday that the partnership is aimed at making AI a driver of innovation in the company’s drug research and development process.
“Partnering with AWS is a step towards making AI a driver of innovation at Novo Nordisk,” Doustdar said.
The hub will utilise AWS AI technology to process data and generate insights that are expected to shorten the process from therapeutic target identification to first dosing in humans.
Under the agreement, Novo Nordisk has designated AWS as its preferred cloud provider and strategic AI partner. The collaboration combines Novo Nordisk’s expertise in chronic disease therapies with AWS cloud and AI services as well as technology infrastructure to support the company’s research and operations.
Novo Nordisk said its previous collaboration with AWS has produced a number of achievements, including reducing the time required for clinical documentation and improving productivity for more than 25,000 employees.
The new partnership also includes the use of Amazon Bio Discovery and Amazon Bedrock services to help identify therapeutic targets, design new therapies, and connect genomic, imaging, and clinical data.
Data and findings from early-stage research are expected to be used to support the design of clinical trials.
Meanwhile, Novo Nordisk will utilise Amazon Bedrock AgentCore to improve operational efficiency through the use of AI agents.
AWS CEO Matt Garman said the partnership is directed at accelerating the drug discovery and development process while maintaining security in data processing.
“Every part of our work with Novo Nordisk ultimately comes back to one thing: getting the right medicines to patients faster,” Garman said.
In addition to the partnership with AWS, Novo Nordisk is also collaborating with a number of Amazon business units, including Amazon Pharmacy, Amazon Ads, and Amazon One Medical, to support the development of new ways to market and deliver therapies to patients.
Source: jawawa.id (https://jawawa.id/newsitem/novo-nordisk-and-aws-accelerate-drug-discovery-with-ai-1787212500)
Originally published by Antara (Indonesian) (https://www.antaranews.com/berita/5703116/novo-nordisk-dan-aws-percepat-penemuan-obat-dengan-ai), translated from Indonesian